156 related articles for article (PubMed ID: 9616143)
1. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma.
Tricot G; Gazitt Y; Leemhuis T; Jagannath S; Desikan KR; Siegel D; Fassas A; Tindle S; Nelson J; Juttner C; Tsukamoto A; Hallagan J; Atkinson K; Reading C; Hoffman R; Barlogie B
Blood; 1998 Jun; 91(12):4489-95. PubMed ID: 9616143
[TBL] [Abstract][Full Text] [Related]
2. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.
Michallet M; Philip T; Philip I; Godinot H; Sebban C; Salles G; Thiebaut A; Biron P; Lopez F; Mazars P; Roubi N; Leemhuis T; Hanania E; Reading C; Fine G; Atkinson K; Juttner C; Coiffier B; Fière D; Archimbaud E
Exp Hematol; 2000 Jul; 28(7):858-70. PubMed ID: 10907648
[TBL] [Abstract][Full Text] [Related]
3. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.
Tricot G; Jagannath S; Vesole D; Nelson J; Tindle S; Miller L; Cheson B; Crowley J; Barlogie B
Blood; 1995 Jan; 85(2):588-96. PubMed ID: 7529066
[TBL] [Abstract][Full Text] [Related]
5. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells.
Lemoli RM; Fortuna A; Motta MR; Rizzi S; Giudice V; Nannetti A; Martinelli G; Cavo M; Amabile M; Mangianti S; Fogli M; Conte R; Tura S
Blood; 1996 Feb; 87(4):1625-34. PubMed ID: 8608257
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
7. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.
Desikan KR; Barlogie B; Jagannath S; Vesole DH; Siegel D; Fassas A; Munshi N; Singhal S; Mehta J; Tindle S; Nelson J; Bracy D; Mattox S; Tricot G
J Clin Oncol; 1998 Apr; 16(4):1547-53. PubMed ID: 9552064
[TBL] [Abstract][Full Text] [Related]
8. Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma.
Lemoli RM; Fortuna A; Raspadori D; Ventura MA; Martinelli G; Gozzetti A; Leopardi G; Ratta M; Cavo M; Tura S
Leuk Lymphoma; 1997 Dec; 26 Suppl 1():1-11. PubMed ID: 9570675
[TBL] [Abstract][Full Text] [Related]
9. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
10. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support.
Jagannath S; Vesole DH; Glenn L; Crowley J; Barlogie B
Blood; 1992 Oct; 80(7):1666-72. PubMed ID: 1391937
[TBL] [Abstract][Full Text] [Related]
11. Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells.
Gazitt Y; Reading CC; Hoffman R; Wickrema A; Vesole DH; Jagannath S; Condino J; Lee B; Barlogie B; Tricot G
Blood; 1995 Jul; 86(1):381-9. PubMed ID: 7540887
[TBL] [Abstract][Full Text] [Related]
12. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
Negrin RS; Kusnierz-Glaz CR; Still BJ; Schriber JR; Chao NJ; Long GD; Hoyle C; Hu WW; Horning SJ; Brown BW
Blood; 1995 Jun; 85(11):3334-41. PubMed ID: 7538824
[TBL] [Abstract][Full Text] [Related]
13. Low-dose peripheral blood stem cell graft after high-dose chemotherapy - an evaluation of hematopoietic reconstitution.
Sauer S; Pavel P; Schmitt A; Cremer M; Kriegsmann M; Bruckner T; Jordan K; Wuchter P; Müller-Tidow C; Kriegsmann K
BMC Cancer; 2020 Apr; 20(1):353. PubMed ID: 32334570
[TBL] [Abstract][Full Text] [Related]
14. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma.
Schiller G; Vescio R; Freytes C; Spitzer G; Sahebi F; Lee M; Wu CH; Cao J; Lee JC; Hong CH
Blood; 1995 Jul; 86(1):390-7. PubMed ID: 7540888
[TBL] [Abstract][Full Text] [Related]
15. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
16. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization.
Watts MJ; Sullivan AM; Leverett D; Peniket AJ; Perry AR; Williams CD; Devereux S; Goldstone AH; Linch DC
J Clin Oncol; 1998 Apr; 16(4):1554-60. PubMed ID: 9552065
[TBL] [Abstract][Full Text] [Related]
17. Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma.
Desikan KR; Jagannath S; Siegel D; Nelson J; Bracy D; Barlogie B; Tricot G
Leuk Lymphoma; 1998 Feb; 28(5-6):501-8. PubMed ID: 9613979
[TBL] [Abstract][Full Text] [Related]
18. Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor.
Schenkein DP; Koc Y; Alcindor T; Stadtmauer EA; Miller KB; Cooper BW; Partridge AH; Lazarus HM
Biol Blood Marrow Transplant; 2000; 6(4A):448-55. PubMed ID: 10975514
[TBL] [Abstract][Full Text] [Related]
19. Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.
Bacigalupo A; Van Lint MT; Valbonesi M; Lercari G; Carlier P; Lamparelli T; Gualandi F; Occhini D; Bregante S; Valeriani A; Piaggio G; Pitto A; Benvenuto F; Figari O; De Stefano G; Caimo A; Sessarego M
Blood; 1996 Jul; 88(1):353-7. PubMed ID: 8704195
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
